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Abstract
Prostate cancer (PCa) is the second leading cause of cancer-related death afflicting United
States males. Most treatments to-date for metastatic PCa include androgen-deprivation
therapy and second-generation anti-androgens such as abiraterone acetate and enzaluta-
mide. However, a majority of patients eventually develop resistance to these therapies and
relapse into the lethal, castration-resistant form of PCa to which no adequate treatment
option remains. Hence, there is an immediate need to develop effective therapeutic agents
toward this patient population. Imidazopyridines have recently been shown to possess Akt
kinase inhibitory activity; thus in this study, we investigated the inhibitory effect of novel imi-
dazopyridine derivatives HIMP, M-MeI, OMP, and EtOP on different human castration-
resistant PCa cells. Among these compounds, HIMP and M-MeI were found to possess
selective dose- and time-dependent growth inhibition: they reduced castration-resistant
PCa cell proliferation and spared benign prostate epithelial cells. Using LNCaP C-81 cells
as the model system, these compounds also reduced colony formation as well as cell adhe-
sion and migration, and M-MeI was the most potent in all studies. Further investigation
revealed that while HIMP primarily inhibits PCa cell growth via suppression of PI3K/Akt sig-
naling pathway, M-MeI can inhibit both PI3K/Akt and androgen receptor pathways and
arrest cell growth in the G2 phase. Thus, our results indicate the novel compound M-MeI to
be a promising candidate for castration-resistant PCa therapy, and future studies investigat-
ing the mechanism of imidazopyridine inhibition may aid to the development of effective
anti-PCa agents.
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Introduction
Prostate cancer (PCa) remains the most commonly diagnosed solid tumor and the second lead-
ing cause of cancer-related death in United States men, maintaining a need for new effective
treatment options [1]. Currently, androgen-deprivation therapy (ADT) is the standard course
of treatment for metastatic PCa, however, most PCa patients relapse within 1–3 years and
develop castration-resistant (CR) PCa which is unresponsive to ADT [2,3,4]. In 2004, a combi-
nation of docetaxel and prednisone was shown to increase patient median survival by 2–3
months, making it the standard-of-care treatment for CR PCa [5]. Recently, the FDA has
approved additional compounds such as novel taxane chemotherapeutic cabazitaxel [6],
androgen synthesis inhibitor abiraterone acetate [7], AR signaling inhibitor enzalutamide [8],
immunotherapeutic sipuleucel-T [9], and bone micro-environment-targeted radiopharmaceu-
tical alpharadin (Radium-223) for treating CR PCa [10]. However, these treatment options are
only able to prolong survival by a few months and the average period of CR PCa patient sur-
vival remains less than two years [11]. Despite advancements in post-ADT treatment strategies,
CR PCa remains an incurable disease; thus there is a great need for alternative therapeutic
options.
While androgen insensitivity can be manifested in multiple ways; one proposed alternative
mechanism is the increased activation of Akt signaling under androgen deprived conditions.
Akt is known to regulate cell cycle, metabolism, angiogenesis, and cell survival in PCa and its
activation may contribute to tumor resistance to ADT and anti-androgens [12,13]. One mecha-
nism through which Akt may contribute to PCa survivability is via modulation of androgen
receptor (AR) signaling. In addition to inducing cell growth, AR also has a role in regulating
apoptosis. Upon phosphorylation of AR at Ser-210 and Ser-790 by Akt, AR-mediated apopto-
sis is suppressed. Through this mechanism, enhanced Akt activity in PCa may contribute to
PCa survivability upon ADT [13]. Indeed, genetic loss and/or mutations in the phosphatidyli-
nositol-3 kinase (PI3K)/Akt pathway that lead to signal deregulation may present in up-to 42%
of primary prostate tumors and over 90% of metastatic tumors, making it a priority next-in-
line therapeutic target [14]. Recently, investigations into imidazopyridines, a novel class of
compounds containing aromatic aldehydes and a pyridine group, have demonstrated these
compounds possess potent Akt kinase inhibitory activity [15–17]. Data shows these com-
pounds have an anti-proliferative effect against CR PCa cells with the ability to simultaneously
inhibit AR and PI3K/Akt/mTOR signaling pathways, making them promising therapeutic
agents [18].
To investigate imidazopyridines’ efficacy for PCa therapy, the LNCaP progressive cell
model, originally characterized in Lin et. al. JBC 1998, was used as the primary cell model in
this study. LNCaP C-81 cells are androgen-independent (AI), express prostate-specific antigen
(PSA) in the absence of androgens, and gain the ability to synthesize testosterone from choles-
terol under steroid-reduced (SR) conditions [19–22]. C-81 cells also possess enhanced prolifer-
ation, ability to form colonies, and migratory potential [21,23]. Most Importantly, LNCaP C-
81 cells retain AR expression and correspond to the expression of AR in the majority of PCa as
well as advanced CR PCa [19]. This makes them a superior cell model for therapeutic studies
when compared to many other PCa cell lines. Other cell lines selected for this study include
MDA PCa2b-AI, PC-3, and RWPE1. Upon passage, MDA PCa2b cells behave similarly to
LNCaP cells and shift from androgen-sensitive (AS) at low passage to AI at high passage. MDA
PCa2b-AI (MDA-AI) cells also retain AR expression and possess enhanced tumorgenicity; this
makes MDA-AI and LNCaP C-81 preferable cell models for studying prostate adenocarci-
noma. Further, due to the ability of imidazopyridine derivatives to target both Akt and AR
pathways, it is prudent to investigate the compounds’ effects on AR-negative PC-3 cells to
Novel Imidazopyridines in Castration-Resistant Prostate Cancer
PLOS ONE | DOI:10.1371/journal.pone.0131811 June 29, 2015 2 / 20
data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
determine their efficacy in cells which lack classic androgen signaling mechanisms. In addition,
PC-3 cell lines are more representative of small-cell neuroendocrine carcinoma than more clin-
ically predominant adenocarcinoma [24]; therefore this cell line should be used in conjunction
with models such as LNCaP and MDA PCa2b cell lines to expand clinical utility. Finally,
immortalized benign prostate epithelium RWPE1 cells act as a control to gauge the selectivity
of the imidazopyridine derivative compounds. Thus our cell models clearly represent the
majority of molecular events observed in clinical implementations of modern PCa therapies.
Our results demonstrate these imidazopyridine derivatives are able to suppress human PCa
cell proliferation in a dose- and time-dependent manner. Importantly, compound M-MeI
exhibited selective potency against CR PCa cell proliferation in comparison to benign prostate
epithelial cells. Furthermore, this compound was also found to inhibit cell migration, adhesion,
and in vitro tumorigenicity. Our data is the first to demonstrate the anti-tumor effect of novel
imidazopyridine derivatives HIMP, M-MeI, OMP, and EtOP on CR PCa cells and indicates
M-MeI to be a promising lead therapeutic agent for future studies.
Materials and Methods
Materials
RPMI 1640 medium, Keratinocyte SFMmedium, gentamicin, and L-glutamine were purchased
from Invitrogen (Carlsbad, CA). Fetal bovine serum (FBS) and charcoal-treated FBS were
obtained from Atlanta Biologicals (Lawrenceville, GA). Molecular biology-grade agarose was
procured from Fisher Biotech (Fair Lawn, NJ). Protein molecular weight standard markers,
acrylamide, and Bradford protein assay kit were purchased from Bio-Rad (Hercules, CA). Poly-
clonal antibodies (Abs) recognizing all three isoforms of Shc protein (#29807, 1:4000) were
purchased from Upstate (Lake Placid, NY). Anti-AR (#C1411, 1:400), anti-cyclin B1 (#K1907,
1:1000), anti-cyclin D1 (#A2712, 1:1000), anti-BclXL (#F111, 1:1000), anti-Bax (#G241, 1:1000),
anti-PCNA (#G261, 1:3000), anti-p53 (#K2607, 1:1000), anti-PSA (#E1812, 1:2000), anti-Sur-
vivin (#C271, 1:2000), and horseradish peroxidase-conjugated anti-mouse (#C2011, 1:5000),
anti-rabbit (#D2910, 1:5000), anti-goat (#J0608, 1:5000) IgG Abs were all obtained from Santa
Cruz Biotechnology (Santa Cruz, CA). Anti-phospho-Akt (Ser473) (#GA160, 1:1000), anti-Akt
(#C1411, 1:2000), Anti-phospho-Stat5 (Y694) (#9351S, 1:4000), and anti-Stat5 (#9363, 1:2000)
Abs were from Cell Signaling Technology (Beverly, MA). Anti-β-actin (#99H4842, 1:10000)
Abs and 5α-dihydrotestosterone (DHT) were procured from Sigma (St. Louis, MO). Imidazo-
pyridine derivatives HIMP (3-phenyl-1-(pyridine-2-yl)imidazo[1,5-a]pyridine), M-MeI (1-
(pyridine-2-yl)-3-(m-tolyl)imidazo[1,5-a]pyridine), OMP (1-(pyridine-2-yl)-3-(o-tolyl)imi-
dazo[1,5-a]pyridine), and EtOP (3-(4-ethoxyphenyl)-1-(pyridine-2-yl)imidazo[1,5-a]pyri-
dine) were synthesized and provided by Dr. Xiu Bu as previously described [18,25] and their
structures are shown in Fig 1. For ease of reading, chemical abbreviations are used throughout
the text.
Cell Culture
Human prostate carcinoma cell lines LNCaP, MDA PCa2b, PC-3, and immortalized benign
prostate epithelial RWPE1 cells were originally obtained from the American Type Culture Col-
lection (Rockville, MD, USA). LNCaP and PC-3 cells were routinely maintained in RPMI 1640
medium containing 5% FBS, 2 mM glutamine, and 50 μg/ml gentamicin [19,21]. MDA PCa2b
cells were maintained in BRFF-HPC1 medium containing 20% FBS, 2 mM glutamine and
50 μg/ml gentamicin [26,27]. As reported previously, the LNCaP progressive cell model was
established in which LNCaP cells at or below passage 33 are designated as C-33 and those at or
greater than passage 81 as C-81. While C-33 cells are sensitive to androgen-induced growth, C-
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81 cells are AI, express higher basal levels of PSA, and gain the ability to synthesize testosterone
from cholesterol [19–22]. Similar to the LNCaP model, upon passage, MDAPCa2b cells
become AI and possess many biochemical properties of clinical CR PCa, including the expres-
sion of functional AR, PSA secretion, and rapid cell proliferation in androgen-deprived condi-
tions [19,21,22,27,28]. RWPE1 cells were cultured in Keratinocyte-SFM supplemented with
bovine pituitary extract (25 μg/ml) and recombinant epidermal growth factor (0.15 ng/ml)
along with 50 μg/ml gentamicin.
To mimic conditions of clinical ADT, cells were maintained in SR conditions, i.e., phenol
red-free RPMI 1640 medium containing 5% charcoal/dextran-treated FBS, 2 mM glutamine,
and 50 μg/ml gentamicin plus 1 nM DHT. Imidazopyridine derivatives HIMP, M-MeI, OMP,
and EtOP were dissolved in dimethyl sulfoxide (DMSO) at 20 mM stock concentrations, stored
at -20°C and diluted as needed for experimental conditions in the respective medium.
Cell Proliferation Assays
For cell proliferation experiments under regular conditions, LNCaP C-81 and MDA PCa2b-AI
cells were seeded in regular culture medium and allowed to grow for 3 days, then changed to
medium containing the respective compound and cultured for an additional 3 days. To deter-
mine cell proliferation under SR conditions, LNCaP C-81, MDA PCa2b-AI, PC-3, and RWPE1
cells were seeded in regular conditions and allowed to grow for 3 days. Cells were then steroid
starved for 48 hours in SR medium and changed to fresh SR medium containing the respective
compound, then cultured for an additional 3 days. Control groups received solvent DMSO
alone. At the specified time point, cells were trypsinized and live cell numbers were counted via
Trypan Blue Exclusion assay using a Cellometer Auto T4 Image-based cell counter (Nexcelom,
MA, USA).
Cell Growth Kinetic and Dosage Determinations
Dose-dependent assays were conducted on LNCaP C-81 cells in the same manner as cell prolif-
eration assays and used medium containing 0, 1, 5, or 10 μM of specified compound. To deter-
mine the kinetic effect of HIMP and M-MeI on the growth of LNCaP C-81 cells, cells were
seeded into six-well culture plates at a density of 2 x 103 cells/cm2 and maintained in regular
culture conditions for 3 days. Cells were then changed to SR medium and maintained for 2
days. One plate of attached cells was harvested and counted as day 0, and the remaining cells
were changed to their respective treatment medium: Control (DMSO), HIMP, and M-MeI
(10 μM). At each time point, cells were harvested for cell number counting and the remaining
cells were fed with fresh media containing respective treatment compound. After cell number
counting, cell lysates were prepared for Western blot analysis.
Flow Cytometry Analysis
To determine the compounds’ effect on cell cycle, LNCaP C-81 cells were seeded in T25 flasks
at a density of 2 x 103 cells/cm2 in regular medium for 3 days, changed to SR medium for 48
hours, and then fed with fresh SR medium containing 10 μM of specified compound. One set
of cells was harvested after 3, 5, and 7 days of treatment, respectively, by trypsinization. After
cell number counting, an aliquot of cells was pelleted by centrifugation, resuspended in 70%
ethanol, and incubated at 4°C for 30 minutes, then washed with PBS and spun down again by
centrifugation. The DNA of ethanol-fixed cells was stained using Telford Reagent (PBS, pH
7.4, containing 0.1% Triton X-100, 0.1mM EDTA disodium salt, 0.05mg/ml RNase A (50 U/
mg), and 50 mg/ml propidium iodide) at 4°C for 4 hours [29]. Determination of cell cycle
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distribution was carried out using a Becton-Dickinson fluorescence-activated cell sorter
(FACSCalibur, Becton Dickinson, San Jose, CA, USA) at the UNMC Flow Cytometry Core
Facility.
Cell Adhesion Assay
To determine the effect of imidazopyridine derivatives on PCa cell adhesion to plastic-ware
surfaces, LNCaP C-81 cells were suspended in 5% FBS 1640 RPMI medium containing 10 μM
of respective compounds and incubated for 30 minutes. Cells were then plated in 6-well plates
in triplicates at a density of 3x103 cells/cm2 in respective treatment medium and incubated for
an additional hour. Non-attached cells were carefully washed away and the remaining attached
cells were stained with a 0.2% crystal violet solution containing 50% methanol. The total num-
ber of cells in five fields at 40x magnification per well were counted.
Clonogenic and Soft Agar Colony Formation Assays
The clonogenic cell growth assay on the surface of plastic-wares was conducted as described
previously [23,26]. Briefly, LNCaP C-81 cells were plated into 6-well plates under regular cul-
ture conditions at three densities: 20, 200, and 2,000 cells per well. Cells were incubated over-
night, after which unattached cells were removed and those attached cells were fed with fresh
regular medium containing 10 μM of treatment compound. Cells were grown for 9 days with a
change of fresh medium every three days. On the 10th day, the medium was removed and cells
were washed with ice-cold HEPES-buffered saline, then attached cells were stained with a 0.2%
crystal violet solution containing 50% methanol. The experiment was carried out in duplicate.
The effect of imidazopyridine derivatives on anchorage-independent growth of LNCaP C-
81 cells was assessed by soft agar assay. Briefly, 5x104 cells were seeded into a 0.25% agarose
top layer with a base layer containing 0.3% agarose in 6-well plates. The day after seeding, cell
clusters containing more than one cell were excluded from the study. Cells were then fed with
0.5 mL of fresh regular medium containing the respective compound every 3 days for 4 weeks.
After the experimental period, colonies were stained with a 0.2% crystal violet solution contain-
ing 50% methanol and counted.
Cell Migration Assay
To determine the effect of imidazopyridine derivatives on PCa cell mobility, LNCaP C-81 cell
migration was assessed via Boyden chamber assay. Cells were plated at a density of 5 x 104 cells
into the upper chamber of 24-well plate transwell inserts. Medium containing 10 μM of treat-
ment compound (solvent alone for control) was placed in both upper and lower chambers of
the transwells. Cells were then incubated for 24 hours, after which they were stained with 0.2%
crystal violet solution in 50% methanol, and cells remaining in the upper chamber were
removed via cotton swab. Cells which had migrated through to the lower chamber were
counted at 40x magnification under a microscope.
Immunoblot Analysis
All cells were rinsed with ice-cold HEPES-buffered saline, pH 7.0, harvested via scraping, and
lysed in ice-cold lysis buffer containing protease and phosphatase inhibitors. Total cellular
lysates were prepared as previously described [19,30]. The protein concentration of the super-
natant was determined using a Bio-Rad Bradford protein-assay. For immunoblotting, an ali-
quot of total cell lysate was electrophoresed on SDS-polyacrylamide gels (7.5%-12%). After
being transferred to nitrocellulose membrane, membranes were blocked with 5% non-fat milk
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in Tris-buffered saline (TBS) containing 0.1% Tween-20 for 30 minutes at room temperature.
Membranes were incubated with the corresponding primary Ab overnight at 4°C. Membranes
were then rinsed and incubated with the appropriate secondary Ab for 60 minutes at room
temperature. Proteins of interest were detected by an enhanced chemiluminescence (ECL)
reagent kit and β-actin was used as a loading control.
Statistical Analysis
Each set of experiments was conducted in duplicate or triplicate as specified in the figure leg-
ends, and experiments were repeated independently at least two or three times. The mean and
standard error values of all results were calculated and two-tailed student-t test was used to
determine significance of results. p<0.05 was considered statistically significant.
Results
Dose-Dependent Effect of Imidazopyridine Derivatives on CR PCa cell
Proliferation
LNCaP C-81 cells exhibit many biochemical properties as seen in clinical CR PCa, including
functional AR expression, AI PSA secretion, and proliferation with intracrine growth regula-
tion [19,21–23] and thus were used as the primary cell model system for testing imidazopyri-
dine compounds. Initially, the dose-dependent effects of HIMP, M-MeI, OMP, and EtOP on
LNCaP C-81 cells were tested under regular culture conditions. Cells were treated with
0–10 μM of each compound for 72 hours and cell growth was analyzed via Trypan Blue exclu-
sion assay. Under regular culture conditions, dose-dependent inhibition of cell proliferation
was observed for all compounds with estimated IC50 values of 6.1 μM (M-MeI), 6.6 μM
(EtOP), 7.3 μM (OMP), and 9.3 μM (HIMP) (Fig 2A).
We then examined the effect of the compounds in SR conditions, mimicking ADT condi-
tions. The compounds inhibited cell growth following the dosage response with estimated IC50
values of 10.2 μM (M-MeI), 10.5 μM (OMP), 11.6 μM (HIMP), and 16.0 μM (EtOP) (Fig 2A).
Interestingly, M-MeI had the greatest inhibitory activity under both growth conditions.
Though EtOP had comparable inhibition to M-MeI in regular conditions, it had the least effect
under SR conditions. HIMP and OMP were also shown to be less effective than M-MeI under
both treatment conditions.
Selective Anti-Proliferative Effect of Compounds on PCa vs.
Immortalized Normal Prostate Epithelial Cells
The suppressive effect of each inhibitor on proliferation was investigated using a panel of
cancerous and benign prostate epithelial cell lines. AI PCa cells including AR-positive LNCaP
C-81 and MDA PCa2b-AI as well as AR-negative PC-3 cells were chosen as representatives of
advanced CR PCa. RWPE1 cells, an immortalized benign prostate epithelial cell line, were used
to determine the compounds’ selectivity. After three days of 10 μM treatment under SR condi-
tions, HIMP, M-MeI, and EtOP all displayed selective inhibition of proliferation of cancerous
cells with significantly less effect on non-cancerous RWPE1 cells (Fig 2B). Though OMP was
effective against C-81 and PC-3 cells, it was comparatively potent against RWPE1 cells. Overall,
the results show HIMP and M-MeI were the most selective, inhibiting PCa cell growth signifi-
cantly more than RWPE1 cells with M-MeI displaying greater inhibition in all cell lines
analyzed.
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Fig 2. Effects of imidazopyridine derivatives on the proliferation of prostate epithelial cells. (A) Dosage effect of Imidazopyridine derivatives on
LNCaP C-81 cells. Cells were plated in six-well plates at 2 x 103 cells/cm2 in regular medium and grown for 72 hours. One set of cells was then fed with fresh
regular medium containing 0,1,5, or 10 μM imidazopyridine derivatives with solvent alone for control and grown for an additional 72 hours. Another set of cells
was first steroid starved in SRmedium for 48 hours then treated with respective compounds in fresh SRmedia containing 1 nM DHT for 72 hours. All cells
were trypsinized and live cell numbers were counted. The experiment was conducted in duplicate wells with 3 sets of independent experiments. The results
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Suppression of PCa Tumorigenicity by Imidazopyridine Derivatives
The compounds’ ability to suppress colony formation in LNCaP C-81 cells was initially
accessed by in vitro clonogenic assays for anchorage-dependent cell growth. LNCaP C-81 cells
were seeded with 20, 200, and 2,000 cells per well in 6-well plates, and then treated with 10μM
of each compound. Upon 10-days of treatment, all compounds significantly inhibited clono-
genic growth at 2,000 cells per well as shown in Fig 3A for 2,000 cells per well. While M-MeI
and EtOP strongly inhibited colony growth, HIMP and OMP were comparatively less potent.
Minimal colony formation was observed at densities of 20 and 200 cells per well.
The soft agar colony formation assay was then performed to determine the compounds’
effect on anchorage-independent growth in a 3-dimentional environment. As shown in Fig 3B,
cells cultured at a density of 5,000 cells per 35 mm dish for four weeks produced far fewer colo-
nies with smaller colony size when treated with the imidazopyridine derivatives. Compared to
control cells treated with solvent alone, M-MeI suppressed colony growth to the greatest extent,
reducing the number of colonies by 90 percent with barely visible colony size (Fig 3B). In com-
parison, EtOP and OMP reduced colony growth with 80 and 70 percent inhibition, respec-
tively, and HIMP had the least effect at about 50 percent inhibition.
To clarify whether these compounds’ effect on colony formation is in part due to the inhibi-
tion of cell adhesion, the capacity of HIMP, M-MeI, OMP, and EtOP to influence PCa cell adhe-
sion onto the plastic surface of 6-well plates was then investigated. While these compounds had
varying degrees of suppression on the ability of LNCaP C-81 cells to adhere at a density of
50,000 cells per well, a similar inhibitory trend was observed to that of clonogenic and soft agar
assays (Fig 3C vs. 3A & 3B). M-MeI had the greatest effect and was able to reduce cell attach-
ment by about 40 percent. While HIMP and EtOP were also able to significantly inhibit cell
adherence, they did so to a lesser extent; OMP was found to have a minimal effect on the C-81
cells’ ability to attach to the plastic surface. Hence, though all compounds belong to the same
class of molecules, they influence PCa cell colony formation and adhesion differently.
To investigate the inhibitory ability of these compounds on tumor metastasis, their activity
on cell migration was analyzed by transwell migration assay. Interestingly, these compounds
were found to have varying degrees of suppression on PCa cell migration. Fig 3D showed that
both M-MeI and EtOP were able to significantly reduce LNCaP C-81 cell migration via Boyden
Chamber assay over a period of 24 hours by about 30 percent. Comparatively, HIMP and
OMP failed to significantly reduce cell migration. Overall, M-MeI was found to exhibit the
most potent inhibitory activity on CR PCa cell tumorgenicity.
Effect of Imidazopyridine Compounds on Proliferative and Apoptotic
Signaling in CR PCa Cells
It is well established that the majority of CR PCa cells express functional AR which is still
required for their growth and survival [22,31,32]. To determine how the compounds suppress
PCa cell proliferation, we analyzed their effects on proliferative and apoptotic signaling in AR-
positive LNCaP C-81 and MDA PCa2b-AI cells under SR conditions. Fig 4A and 4B showed
presented are mean ± SE; n = 2x3. *p<0.05 **p<0.005 ***p<0.0005. (B) Effects of imidazopyridine derivatives on the growth of various PCa cells and
immortalized prostate epithelial cells. All cells were plated in six-well plates at the noted density in their respective medium for three days, steroid-starved for
two days, then fed with fresh SRmedium with 1 nM DHT containing 10 μM imidazopyridine derivatives and grown for three additional days. Cells were
trypsinized and live cell number was counted. LNCaP C-81–2 x 103 cells/cm2, MDA PCab2b AI—3 x 103 cells/cm2, PC-3–2 x 103 cells/cm2, RWPEI– 7.5
x103 cells/cm2. All experiments were performed in triplicate wells with 3 sets of independent experiments. Results presented are mean ± SE; n = 3x3.
*p<0.05; **p<0.001; ***p<0.0001.
doi:10.1371/journal.pone.0131811.g002
Novel Imidazopyridines in Castration-Resistant Prostate Cancer
PLOS ONE | DOI:10.1371/journal.pone.0131811 June 29, 2015 9 / 20
Fig 3. Effects of imidazopyridine derivatives on the tumorigenicity of LNCaP C-81 cells. (A) Clonogenic assay on plastic wares. LNCaP C-81 cells
were plated in six-well plates at densities of 20, 200, and 2,000 cells/well. After 24 hours, attached cells were treated with respective compounds at 10 μM
concentrations of imidazopyridine derivatives or solvent alone as control. Cells were fed on days 3, 6, and 9 with fresh culture media containing respective
inhibitors. On day 10, cells were stained and the number of colonies counted. The photos of representative colony plates were taken from plates seeded with
2,000cells/well, and the number of colonies shown was counted also from plates seeded with 2,000cells/well. Minimal colony formation was observed at
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that, upon 3-day treatments, 10 μM of each compound significantly suppressed LNCaP C-81
and MDA PCa2b-AI cell proliferation.
In LNCaP C-81 cells under SR conditions, though imidazopyridines are known for Akt
inhibition, only HIMP and M-MeI inhibited Akt activation as shown by decreased Ser473
phosphorylation (Fig 4C) [15]. Additionally, while all compounds reduced AR protein levels in
LNCaP C-81 cells; M-MeI and EtOP were more potent. Importantly, a similar trend was
observed in AR-regulated pro-proliferative proteins. M-MeI and EtOP reduced levels of
p66Shc, a 66kDa Src-homologous collagen homologue, cyclin D1, and PCNA, while HIMP and
OMP had minimal effects [33–36]. We also analyzed Stat5 phosphorylation at Y694, which
aids in the translocation of AR to the nucleus and is a regulator of cylcin D1 synthesis [37,38].
Unexpectedly, M-MeI slightly increased Stat5 activation in C-81 cells while EtOP suppressed
activation; HIMP and OMP had no effect. Though all compounds diminished anti-apoptotic
Survivin protein, their treatment elevated BclXL, another anti-apoptotic protein [39,40]. The
compounds’ effect on p53, a regulator of cell survival and inducer of apoptosis, varied with
M-MeI slightly lowering p53 levels, and EtOP slightly increasing them; HIMP and OMP had
no significant effect [41].
As shown in Fig 4D, in MDA PCa2b-AI cells under SR conditions, AR inhibition was simi-
lar to that of LNCaP C-81 cells: M-MeI and EtOP greatly suppressed AR levels while HIMP
and OMP had minimal effects. This also correlated with lower levels of AR-regulated p66Shc,
cyclin D1, and PCNA in M-MeI-treated cells, all of which promote cell growth. As seen in C-81
cells, in MDA PCa2b-AI cells HIMP and OMP had no inhibitory effect on Stat5 activation,
while EtOP suppressed Y695 phosphorylation. M-MeI, however, strongly reduced Stat5 phos-
phorylation in MDA PCa2b-AI cells where it had increased it in C-81 cells. Also, while the
compounds’ effect on p53 remained similar in MDA-AI cells compared to C-81 cells, their
effects on anti-apoptotic Survivin and BclXL proteins were altered. In MDA-AI cells, HIMP,
OMP and EtOP increased levels of Survivin while BclXL remained unchanged relative to con-
trol cells suggesting these proteins are not essential to growth inhibition. Because Akt phos-
phorylation at Ser473 in MDA PCa2b-AI cells was undetectable under SR conditions, these
cells were instead treated in regular culture medium for three days and all compounds were
found to reduce Akt activation (Fig 4E).
In summary, of the four compounds tested, M-MeI was the most potent inhibitor of prolif-
eration in both LNCaP C-81 and MDA PCa2b-AI cell lines under SR conditions. It also consis-
tently reduced AR and AR-regulated proteins as well as Akt Ser473 phosphorylation in both
cell lines, suggesting these pathways are involved in imidazopyridine inhibition of CR PCa cell
growth.
densities of 20 and 200 cells/well. Results presented are mean ± SE; n = 2x3. ***p<0.0001. (B) Anchorage-independent soft agar assay. LNCaP C-81 cells
were plated at a density of 5 x 104 cells/35mm dish in 0.25% soft agar plates. The following day, cells in doublets or greater were marked and excluded from
the study. Media were added every three days, and at the end of 5 weeks, colonies formed were stained and counted. Representative images of colonies are
shown (above) and the colony number was counted (below). The experiments were performed in duplicate with 3 sets of independent experiments. Results
presented are mean ± SE; n = 2x3. *** p<0.0001. (C). Cell adhesion assay on plastic wares. Cells were suspended in treatment media for 30 minutes before
being plated in 6-well plates at 3 x103 cells/cm2 using the same treatment media. Cells were allowed to adhere for one hour, fixed and stained by 0.2% crystal
violet solution (50:50, water:MeOH). The total number of cells in five fields at 40x magnification for each well was counted. The experiments were performed
in triplicate with 3 sets of independent experiments. Results presented are mean ± SE; n = 3x3. *p<0.05; **p<0.01. (D). Cell migration transwell assay. Cell
migration was assessed via Boyden chamber. An aliquot of 5 x 104 C-81 cells was seeded in the insert of 24-well plates in media containing 10 μM respective
compounds with solvent alone for control in both upper and lower chambers. After 24-hour incubation, the migrated cells were stained and those cells
remaining in the upper chamber were removed via cotton swab. Cells which had migrated through to the lower chamber were counted. Representative
images are shown at 40x magnification. The experiments were performed in triplicate with 3 sets of independent experiments, and the results presented are
mean ± SE; n = 3x3, *p<0.05; **p<0.005.
doi:10.1371/journal.pone.0131811.g003
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Fig 4. Effects of imidazopyridine derivatives on PCa proliferative and apoptotic signaling under SR conditions. (A) LNCaP C-81 cells were plated in
triplicate in T25 flasks at 4 x 103 cells/cm2 in regular medium, grown for 72 hours then steroid starved for 48 hours. Cells were then treated with 10 μM
imidazopyridine derivatives or DMSO as control for an additional 72 hours under SR conditions. Cells were trypsinized and live cell numbers counted via
Trypan Blue assay. The experiments were performed in triplicate with 3 sets of independent experiments. *** p<0.0005. (B)MDA PCa2b-AI cells were
grown, treated, and counted under conditions as described above in (A) for LNCaP C-81 cells. Results presented are mean ± SE; n = 3x3. *p<0.05;
**p<0.005; ***p<0.0005. (C) LNCaP C-81 total cell lysate proteins were collected from (A) after cell number counting. Those cells were grown in SR
conditions and analyzed for phosphorylated Akt and STAT5, as well as total AR, Akt, Shc, p53, cyclin B1, cyclin D1, PCNA, BclXL, and Survivin protein levels.
β-actin protein level was used as a loading control. Similar results were observed in two sets of independent experiments. (D)MDA PCa2b-AI total cell lysate
proteins from (B) after cell number counting. Cells were grown in SR conditions and analyzed for phosphorylated STAT5, as well as total AR, Shc, p53, cyclin
B1, cyclin D1, PCNA, BclXL, and Survivin protein levels. β-actin protein level was used as a loading control. Similar results were observed in three sets of
independent experiments. (E)MDA PCa2b-AI total cell lysate proteins from cells grown in regular conditions were analyzed for phosphorylated Akt and total
Akt. β-actin protein level was used as a loading control. Similar results were observed in three sets of independent experiments.
doi:10.1371/journal.pone.0131811.g004
Novel Imidazopyridines in Castration-Resistant Prostate Cancer
PLOS ONE | DOI:10.1371/journal.pone.0131811 June 29, 2015 12 / 20
Kinetic Effect of HIMP and M-MeI on LNCaP C-81 Cells under SR
Conditions
Since HIMP and M-MeI exhibited the most selectively potent activity, these two compounds
were investigated further by kinetic analysis in LNCaP C-81 cells under SR conditions for clini-
cal relevance. As shown in Fig 5A, both HIMP and M-MeI began to show significant inhibition
of cell proliferation on day three of treatment, and this trend continued through day seven. It
should also be noted M-MeI exhibited greater growth suppression than HIMP at every time
point analyzed.
Cell lysates were collected from each time point and Western Blot analysis was performed
(Fig 5B). Our results showed M-MeI-treated cells had decreased levels of AR and PSA, an
androgen-regulated protein, as well as cell cycle proteins cyclin B1 and PCNA as seen at 5-day
treatment. Meanwhile, HIMP treatment decreased PSA protein level upon 7-day treatment but
not AR protein level. A similar trend was observed in pro-proliferation proteins as HIMP had
no effect on cyclin B1 and marginal effect on PCNA. It should be noted, as the level of active
unphosphorylated cyclin B1 decreased (lower band), the inactive phosphorylated cyclin B1 pro-
tein level increased (upper band) [42]. The data may indicate arrestment of the cell cycle.
We also investigated the effects of HIMP and M-MeI on pro-apoptotic proteins Bax as well
as p53 vs. anti-apoptotic Bcl-XL [40]. Treatment with both compounds dramatically increased
Bax and p53 protein level by day seven and correlated with the observed decrease in cell prolif-
eration. Interestingly, both compounds initially increased Bcl-XL levels on days one and three,
and had no effect on Bcl-XL as treatment continued (Fig 4B). Thus both compounds seem to
induce apoptosis by increasing levels of pro-apoptotic proteins instead of inhibiting anti-apo-
ptotic proteins, while M-MeI also reduces pro-proliferative proteins as well as AR signaling.
To further investigate the kinetic effect of HIMP and M-MeI, cell cycle analysis was per-
formed via flow cytometry. The cell cycle analyses (Fig 5C) revealed that upon 7-day treatment,
M-MeI reduced LNCaP cell proliferation by 50% as indicated by the decreased percentage of
cell population in S phase. M-MeI also increased the percentage of cells undergoing apoptosis
nearly four-fold at day seven relative to control cells. At the same time, HIMP had no signifi-
cant effect on percentage of cells in S phase and increased the percentage undergoing apoptosis
two-fold by day seven. Interestingly, the population of cells treated with M-MeI, but not
HIMP, accumulated in G2 phase following the time course of treatment, i.e., only a marginal
increase on day 3 and about a 50% increase in day 5 (S1 Fig). On day-7, the percentage of cells
in G2 phase doubled to about 49% in M-MeI treated cells compared to 24% in control cells
(Fig 5C). In parallel, on day 7, the HIMP-treated cells were only slightly increased from about
24% to 27% in G2-phase. These results clearly indicate M-MeI blocks cell cycle at G2 phase.
Discussion
Given the poor 5-year 29% survival rate of metastatic CR PCa patients, there is a clear need for
advancement in treatment alternatives [14]. First line treatment of PCa usually involves ADT
by means of surgical castration or chemical castration, such as luteinizing hormone-releasing
hormone treatment, coupled with anti-androgens. Treatment with classic anti-androgens such
as flutamide or bicalutamide (Casodex), which competitively inhibit androgen binding to AR,
can be effective for 1–3 years before patients subsequently become unresponsive and eventually
relapse. Relapse can occur for a number of reasons such as deregulation of AR cofactors, AR
overexpression, splicing mutations resulting in constitutively active AR, or mutations allowing
AR activation by competitive inhibitors [43]. In the case of the latter, upon discontinuation of
flutamide or bicalutamide treatment, patients often experience a period of anti-androgen with-
drawal syndrome (AAWS) characterized by a decline in serum PSA levels and tumor
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Fig 5. Kinetic analysis of HIMP andM-MeI’s effects on LNCaP C-81 cells under steroid-deprived conditions. (A) Cells were plated in six-well plates at
2 x 103 cells/cm2 in regular medium for three days, then steroid-starved for 48 hours followed by treatment with 10 μMHIMP or M-MeI in SRmedium
containing 1 nM DHT. Solvent alone was used for controls. On day 0, 1, 3, 5 and 7, one set of cells in duplicates from each group was harvested for live cell
counting. Remaining cells were replenished with fresh respective medium. The experiments were performed in duplicates with 3 sets of independent
experiments. Results presented are mean ± SE; n = 2x3. *p<0.05; **p<0.005; ***p<0.0005. (B) Total cell lysate proteins from HIMP- and M-MeI-treated C-
Novel Imidazopyridines in Castration-Resistant Prostate Cancer
PLOS ONE | DOI:10.1371/journal.pone.0131811 June 29, 2015 14 / 20
regression [43,44]. In some cases, these patients will respond to treatment with alternative anti-
androgens, however, patients will again eventually become unresponsive to treatment and
develop advanced PCa, commonly referred to as “castration-resistant” (CR) [45]. While more
effective anti-androgens such as enzalutamide, which possesses a 5-fold higher binding affinity
to AR compared to bicalutamide, are now available, mutations allowing AR activation by enza-
lutamide have been reported and tumors continue to become CR over time [46]. The therapeu-
tic effect of second generation anti-androgens such as enzalutamide and abiraterone acetate
implies most cancer cells, which still express functional AR, require AR signaling to evade tra-
ditional regulatory mechanisms to survive androgen deprivation strategies [7,8,47]. Despite the
effectiveness of ADT and anti-androgen treatment strategies to delay the progression of PCa,
many patients still develop the CR phenotype and thus there is an urgent need for alternative
therapeutic targets to AR. Other signaling pathways, such as the PI3K/Akt-mediated cell sur-
vival pathway, may act to supplement the lack of AR stimulation under androgen-deprived
conditions, bypassing the effect of ADT. Therefore, in this study we investigate novel therapeu-
tic agents which are capable of targeting multiple biochemical pathways critical to CR PCa cell
growth and progression.
In this study, four novel imidazopyridine derivatives were investigated to determine their
viability as therapeutic agents for CR PCa. LNCaP C-81 cells were chosen as our primary
experimental cell model because they possess many biochemical properties common to CR
PCa, including expression of functional AR, AI PSA secretion and proliferation, and expression
of enzymes required for the synthesis of androgens from cholesterol [19,21,22,31,47]. We ini-
tially showed that all four compounds are effective inhibitors of CR PCa cell growth in the
LNCaP C-81 cell line model, though to varying degrees with M-MeI as the most potent under
both regular and SR conditions (Fig 2A). Additionally, the effects of the imidazopyridine deriv-
atives on cell proliferation differed between compounds as well as cell lines. Of those com-
pounds investigated, HIMP and M-MeI displayed broad-spectrum growth inhibition of
multiple CR PCa cell lines, including both AR-positive and AR-negative cells. Most impor-
tantly, these compounds exhibited more potent inhibition of proliferation in PCa cells than
benign RWPE1 cells (Fig 2B).
We further investigated the effects of each compound on various biological activities critical
to malignant tumor progression. Colony formation, cell adhesion, and migration are vital
malignant processes exhibited by many cancer cells. In both anchorage-dependent and anchor-
age-independent growth assays, M-MeI and EtOP dramatically reduced the number of colo-
nies formed as well as colony size. This may partially be due to M-MeI and EtOP’s ability to
inhibit cell adhesion. To investigate the effect of these compounds on cell migration, the trans-
well migration assay was used to analyze LNCaP C-81 cell motility. Again, M-MeI and EtOP
were found to be potent inhibitors of C-81 cell migration while HIMP and OMP had no signifi-
cant effect. Interestingly, this correlates with M-MeI and EtOP’s ability to reduce AR protein
level as shown in Fig 4C where HIMP and OMP fail to influence AR. This suggests AR inhibi-
tion may be crucial for the inhibition of these malignant processes. However, while EtOP was
an effective inhibitor of PCa tumorgenicity, it was not as effective at growth suppression as
M-MeI. This may be due to EtOP’s failure to prevent Akt activation whereas M-MeI success-
fully inhibits Akt phosphorylation at S473 (Fig 4C).
81 cells from (A) were collected and analyzed for AR, cPSA, cyclin B1, PCNA, Bax, p53, and Bcl-XL proteins. β-actin protein level was used as a loading
control. (C) Histograms of cell cycle distributions of LNCaP C-81 cells upon 7 days of HIMP and M-MeI treatments. Cells were plated in T25 flasks at 2 x 103
cells/cm2 in regular medium for three days, then steroid-starved for 48 hours followed by treatment with 10 μMHIMP or M-MeI in SRmedium with 1 nM DHT
and solvent DMSO alone as control. One set of cells from each group was harvested after 3, 5, and 7 days treatment for flow cytometric analysis. Similar
results were obtained from two sets of independent experiments. The data shown were representative results of 7-day treatments.
doi:10.1371/journal.pone.0131811.g005
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The PI3K/Akt signaling pathway is proposed to be pivotal to the growth and survival of CR
PCa cells; dysregulation of this pathway is shown to contribute to resistance to treatment
[31,48–54]. In clinical studies, for example, treatment with AR inhibitor bicalutamide is shown
to progressively increase Akt signaling in patients in correlation with their Gleason grades [51].
In parallel, PCa treated with chemotherapeutic agent docetaxel possess increased Akt activa-
tion in patient tumors [52]. Other in vitro studies similarly demonstrated LNCaP cells grown
in SR medium for extended periods of time have increased Akt activation which may compen-
sate for a lack of androgen signaling [12]. Indeed, there is high prevalence of PI3K/Akt/mTOR
pathway activation in CR PCa and emerging studies show inhibitors targeting the PI3K/Akt
pathway are rapidly entering into clinical trials [14,53–55]. Therefore, the PI3K/Akt signaling
axis is a promising next-in-line therapeutic target and its inhibition in conjunction with ADT
and anti-androgens may improve patient survival.
Initially, imidazopyridines have been shown to possess Akt kinase inhibitory activity and
are effective suppressors of tumor growth and advancement in a number of carcinomas,
including PCa [15,16,18]. Interestingly, while all four derivative compounds inhibited Akt
phosphorylation at Ser473 in MDA PCa2b cells; only HIMP and M-MeI inhibited its phos-
phorylation in LNCaP C-81 cells. It should be noted because Akt signaling in MDA PCa2b-AI
cells was too weak to detect under SR conditions, it was observed under regular conditions. It is
thus possible the differential inhibition of Akt activation in MDA-AI vs. LNCaP C-81 cells was
in part due to the difference between regular and SR growth conditions (Fig 4C–4E).
While HIMP is a strong inhibitor of Akt activation in both cells, it fails to consistently
down-regulate AR, a long established target of PCa therapy. Supportively, western blot analysis
showed HIMP inconsistently affects AR protein levels (Figs 4D and 5B), a phenomena which
has previously been observed when CR PCa cells are treated with PI3K/Akt inhibitors [12,18].
Furthermore, HIMP had little shift in potency between regular conditions and SR conditions
(Fig 2A), suggesting HIMP’s mechanism of inhibition is relatively androgen-independent. In
addition, HIMP is a potent inhibitor of Akt phosphorylation at Ser473 and also acts to induce
pro-apoptotic p53 and Bax proteins (Figs 4C, 4D and 5B) [27]. Together, these results suggest
HIMP inhibits CR PCa growth by suppressing cell survivability but not androgen signaling.
While both HIMP and M-MeI were found to have promising selective growth suppression,
M-MeI was shown to have greater efficacy (Figs 2 and 4). M-MeI is a derivative of HIMP, pos-
sessing a methyl group on the para position of the benzene ring (Fig 1). This modification
apparently allows M-MeI to suppress AR protein level as well as Akt activation; there is also a
noticeable change in M-MeI’s IC50 value between regular and SR conditions, indicating its
mechanism of growth inhibition includes the suppression of AR signaling (Fig 4C–4E). Sup-
portively, as shown in Fig 5B, upon M-MeI treatment, there is a consistent, progressive
decrease in AR protein. This coincides with a decrease in PSA, a target of AR, as well as p66Shc
protein level, a protein regulated by androgens which is involved in cell proliferation and apo-
ptosis (Fig 4C and 4D). Downstream pro-proliferative markers, cyclin D1 and PCNA were also
down-regulated over-time to a greater extent by M-MeI compared to HIMP. In addition,
STAT5 signaling is proposed to be involved in the transition from androgen-sensitive to CR
PCa and activated STAT5 can enhance nuclear translocation of AR [40]. Interestingly, as seen
in Fig 4C and 4D, while M-MeI inhibited Stat5 phosphorylation at Y694 in MDA-AI cells, it
increased Y694 phosphorylation in LNCaP cells. This inconsistent effect suggests inhibition of
STAT5 activation is not vital to M-MeI’s suppression of PCa. Furthermore, M-MeI strongly
inhibited the phosphorylation of pro-survival protein Akt (Ser473) (Fig 4C–4E) as well as
induced pro-apoptotic proteins p53 and Bax (Fig 5B) [27]. Thus, M-MeI’s anti-tumorigenic
effect on PCa is due to its strong inhibition of both Akt and AR signaling pathways.
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Unexpectedly, the kinetic analysis revealed an interesting phenomenon: upon HIMP and
M-MeI treatments over time, both compounds, though to a greater extent by M-MeI,
decreased the protein level of active unphosphorylated cyclin B1 (Fig 5B, lower band) and
increased the inactive phosphorylated band (upper band) (Fig 5B) [41]. Cyclin B1, a key regula-
tor of mitosis, is phosphorylated during the G2 phase and becomes unphosphorylated upon
the cell reaching M phase [41]. To validate further, we performed cell cycle analysis on HIMP-
and M-MeI-treated cells by flow cytometry. Compared to control cells, M-MeI-treated cells
had lower percentages of cells in S phase, corresponding with a decrease in cell proliferation,
and twice the percentage of cells in the G2 phase. Minimal changes were observed in HIMP-
treated cells, although both treatments increased the percentage of cells undergoing apoptosis
(Fig 5C). Together, this data indicates these imidazopyridine derivatives function to inhibit the
transition of PCa cells between G2 and M phases, though the exact mechanism remains to be
elucidated.
In summary, our data shows imidazopyridine derivatives exhibit inhibitory activity of
tumorgenicity in CR PCa cells. Each compound displayed differential effects on Akt and AR
signaling pathways, and further studies are needed to determine the mechanism by which
these molecules suppress the growth of CR PCa. Among the four compounds investigated,
M-MeI was found to suppress multiple signaling pathways related to PCa progression, includ-
ing classical target AR as well as the Akt survival pathway, making it a promising candidate for
future therapeutic studies. Importantly, this compound displays selective growth inhibition,
having a significantly greater suppressive effect on PCa compared to benign prostate epithelial
cells. Thus, M-MeI can serve as a lead compound for imidazopyridine side-chain modifica-
tions, which could yield more potent, selective agents to improve the treatment of CR PCa
patients. Future investigation to elucidate M-MeI’s specific mechanism of inhibition and in
vivo studies will help better determine its potential as a therapeutic agent.
Supporting Information
S1 Fig. Histograms of cell cycle distributions of LNCaP C-81 cells upon 3 and 5 days of
HIMP and M-MeI treatments. Cells were plated in T25 flasks at 2 x 103 cells/cm2 in regular
medium for three days, then steroid-starved for 48 hours followed by treatment with 10 μM
HIMP or M-MeI in SR medium with 1 nM DHT and solvent DMSO alone as control. One set
of cells from each group was harvested after 3, 5, and 7 days treatment for flow cytometric anal-
ysis. Similar results were obtained from two sets of independent experiments. The data shown
were representative results of 3- and 5-day treatments.
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